| Literature DB >> 33758811 |
Uday P Pratap1, Lalgi Hima1, Thangamani Kannan1, Chadrasekaran Thyagarajan1, Hannah P Priyanka1, Ramasamy Vasantharekha1, Anand Pushparani2, Srinivasan Thyagarajan1.
Abstract
OBJECTIVES: This study aims to investigate lymphoproliferation, cytokine production, and intracellular signaling molecules in peripheral blood mononuclear cells (PBMCs) isolated from healthy individuals and rheumatoid arthritis (RA) patients to understand the extent of the involvement of these pathways in the pathogenesis of RA. PATIENTS AND METHODS: The study included 65 participants (29 males, 36 females; mean age 51.8±10.3 years; range, 37 to 71 years) who were categorized into four groups as healthy males (n=22, mean age 49.8±10.6 years; range, 39 to 65 years), male RA patients (n=7, mean age 51.8±13.9 years; range, 37 to 68 years), healthy females (n=20, mean age 53.7±8.8 years; range, 42 to 67 years), and female RA patients (n=16, mean age 52.9±10.4 years; range, 40 to 71 years). PBMCs were collected from the participants and analyzed for Concanavalin A (Con A)-induced lymphoproliferation using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, cytokine production, and phospho-signal transducer and activator of transcription 3 (p-STAT-3), phospho-extracellular-signal-regulated kinase (p-ERK), phospho-cAMP response element binding (p-CREB), and phospho-protein kinase B expressions using enzyme-linked immunosorbent assay. Short form of the Arthritis Impact Measurement Scales 2 and multidimensional health assessment questionnaire were used to measure the level of disability and the quality of life.Entities:
Keywords: Autoimmunity; cytokines; inflammation; phospho-cAMP response element binding; signal transducer and activator of transcription 3
Year: 2020 PMID: 33758811 PMCID: PMC7945702 DOI: 10.46497/ArchRheumatol.2020.7481
Source DB: PubMed Journal: Arch Rheumatol ISSN: 2148-5046 Impact factor: 1.472
Demographic and clinical enrollment data of study population
| Healthy controls | Rheumatoid arthritis | ||||||||||
| n | Males | Females | Males | Females | |||||||
| % | Mean±SD | n | % | Mean±SD | n | % | Mean±SD | n | % | Mean±SD | |
| Age (year) | 49.8±10.6 | 53.7±8.8 | 51.8±13.9 | 52.9±10.4 | |||||||
| Number | 22 | 20 | 7 | 16 | |||||||
| Weight (kg) | 66.8±10.6 | 61.5±9.3 | 62.8±7.4 | 62.1±13.7 | |||||||
| Sex (%) | 33.84 | 30.79 | 10.76 | 24.61 | |||||||
| Diseases | |||||||||||
| Diabetes mellitus | 18.18 | 15.00 | 14.28 | 12.50 | |||||||
| Hypertension | 0 | 20.00 | 0 | 3.00 | |||||||
| Education | |||||||||||
| University | 50.00 | 35.00 | 40.00 | 14.00 | |||||||
| School (1st-12th grades) | 50.00 | 60.00 | 60.00 | 76.00 | |||||||
| Uneducated | 0 | 5.00 | 0 | 20.00 | |||||||
| Residency | |||||||||||
| Rural | 50.00 | 10.00 | 42.8 | 37.5 | |||||||
| Urban | 50.00 | 90.00 | 57.2 | 62.5 | |||||||
| Physical condition of the joints | |||||||||||
| Tender joints (no.) | 0.00 | 0.00 | 6.00 | 12.00 | |||||||
| Swollen Joints (no.) | 0.00 | 0.00 | 17.00 | 12.00 | |||||||
| SD: Standard deviation. | |||||||||||
Comparison of AIMS2-SF questionnaire, MDHAQ, anti-CCP, and cortisol levels between healthy individuals and rheumatoid arthritis patients
| Healthy controls (Males) (n=22) | RA (Males) (n=7) | Healthy controls (Females) (n=20) | RA (Females) (n=16) | |||||||||
| Mean±SEM | Median | IQR | Mean±SEM | Median | IQR | Mean±SEM | Median | IQR | Mean±SEM | Median | IQR | |
| AIMS2-SF questionnaire | ||||||||||||
| Physical | 0.73 | 0.73 | ||||||||||
| Symptom (pain) | 0.50 | 0.76 | 0.53 | 2.28 | ||||||||
| Affect | 2.0 | 3.50 | 3.0 | 2.50 | 1.1±3.2 | |||||||
| Social | 2.50 | 3.28 | 3.12 | 3.44 | 4.1±2.0 | 4.37 | 1.71 | |||||
| MDHAQ | ||||||||||||
| Function | 3.04 | 1.97 | 5.12 | 1.55 | 4.91 | 2.65 | 4.94 | 2.47 | ||||
| Pain | 0.94 | 1.76 | ||||||||||
| Patient global estimate | 2.64 | 3.88 | ||||||||||
| RA disease activity index | 2.66 | 1.49 | ||||||||||
| Review of systems (ROS) | 4.71 | 6.46 | 7.95 | 7.08 | 7.95 | 10 | 12.0 | 9.25 | ||||
| RAPID3 | 16.14 | 8.70 | 14.50 | 9.0 | ||||||||
| Anti-CCP level (Units/mL) | 6.5±0.9 | 6.8±1.4 | ||||||||||
| Cortisol level (ng/mL) | 15.4±1.3 | |||||||||||
| AIMS2-SF: Short form of Arthritis Impact Measurement Scales 2; MDHAQ: Multidimensional health assessment questionnaire; Anti-CCP: Anti-cyclic citrullinated peptide; RA: Rheumatoid arthritis; IQR: Interquartile range; RAPID3: Routine assessment of patient index data 3; § Compared to healthy controls, p<0.05; SEM: Standard error of the mean. | ||||||||||||
Regression analysis of serum cortisol anti-CCP levels, pain score, and cytokine production in RA patients
| Regression analysis | RA males | Equation | RA females | P | Equation | |
| Anti-CCP level (Units/mL) vs. serum cortisol (ng/mL) | R2=0.404 | <0.005 | Y=0.7297*X + 11.66 | R2=0.423 | <0.0005 | Y=0.9674*X + 11.97 |
| IL-17 (pg/mL) vs. serum cortisol (ng/mL) | R2=0.378 | <0.01 | Y=0.09575*X + 3.334 | R2=0.691 | <0.0001 | Y=0.218*X - 7.886 |
| Anti-CCP: Anti-cyclic citrullinated peptide; RA: Rheumatoid arthritis; IL: Interleukin; y=mx+c; Where y is dependent variable, m is slope, x is independent variable, and c is intercept for a given line. | ||||||
Antioxidant enzymes activity in male and female healthy participants and those with rheumatoid arthritis
| SOD | CAT | GPx | GST | |
| Groups | Mean±SEM | Mean±SEM | Mean±SEM | Mean±SEM |
| Healthy control (males) | 8.4±0.2 | 116.2±8.6 | 3.5±0.3 | 1.3±0.1 |
| Rheumatoid arthritis (males) | 5.9±0.5* | 42.0±5.2* | 0.5±0.1* | 1.2±0.2 |
| Healthy control (females) | 11.6±0.2 | 155.1±13.8 | 0.9±0.1 | 1.5±0.1 |
| Rheumatoid arthritis (females) | 6.5±0.3* | 71.2±6.0* | 0.3±0.0* | 1.2±0.1* |
| SOD: Superoxide dismutase; CAT: Catalase; GPx: Glutathione peroxidase; GST: Glutathione-S- transferase; SEM: Standard error of the mean; * p<0.05 compared to healthy controls. | ||||